Chemcrux Enterprises announced the cessation of Mr. Bhanubhai Patel and Mr. Shailesh Patel as independent directors on August 23, 2026. The exits follow the completion of their respective terms, with no material reasons cited for the departure.

The company filed the disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Both directors served consecutive five-year terms before stepping down.

Director Cessation Details

Mr. Bhanubhai Patel (DIN: 00727280) and Mr. Shailesh Patel (DIN: 02826895) ceased to be independent directors effective at the end of the day on August 23, 2026. The Board of Directors acknowledged their contributions during their association with the company.

The filing was signed by Dipika Rajpal, Company Secretary and Compliance Officer, on August 24, 2026.

Chemcrux Enterprises reported a 135% year-on-year increase in standalone net profit to ₹137.43 lakh for the quarter ended June 30, 2026, driven by a 31% surge in revenue from operations. The Vadodara-based bulk drug intermediate manufacturer saw its consolidated net profit attributable to owners jump 444% to ₹50.52 lakh during the same period, signaling robust operational scaling and improved bottom-line efficiency.

The Board of Directors approved these unaudited financial results on August 4, 2026, alongside the Limited Review Report from statutory auditors Naresh & Co. The company’s total comprehensive income for the quarter reached ₹159.22 lakh on a standalone basis and ₹72.31 lakh on a consolidated basis, which includes wholly-owned subsidiary Kalichem Private Limited.

Financial Performance Highlights

Revenue from operations stood at ₹2,193.81 lakh on a standalone basis, up from ₹1,674.74 lakh in the corresponding quarter of FY26. On a consolidated basis, revenue was ₹2,193.82 lakh, compared to ₹1,650.35 lakh in Q1FY26. The improvement in profitability was supported by controlled cost structures despite higher material consumption. Standalone cost of materials consumed rose to ₹827.51 lakh from ₹552.72 lakh in Q1FY25, while employee benefits expense increased to ₹259.05 lakh from ₹201.99 lakh. Other expenses remained stable at ₹655.12 lakh compared to ₹434.79 lakh in the previous year.

Basic earnings per share (EPS) improved to ₹0.93 from ₹0.39 on a standalone basis. Consolidated basic EPS rose to ₹0.34 from ₹0.06. Diluted EPS remained identical to basic EPS due to the negligible impact of employee stock options, as disclosed under Ind AS 33.

Corporate Governance and Disclosures

The Board meeting, held at the company’s registered office in Vadodara, also scheduled the 30th Annual General Meeting for September 17, 2026, via video conferencing. Dipika Rajpal, Company Secretary & Compliance Officer, signed the disclosure submitted to BSE Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Naresh & Co., Chartered Accountants, issued their limited review report stating that nothing came to their attention to suggest the statements contained material misstatements. The audit covered both standalone and consolidated results, including procedures for the subsidiary Kalichem Private Limited.

What the Numbers Show

The significant divergence between standalone and consolidated profit growth warrants attention. While standalone PAT surged 135%, consolidated PAT jumped over 440%. This suggests that the subsidiary, Kalichem Private Limited, may have contributed disproportionately to the bottom-line improvement or benefited from specific one-time gains not reflected in the parent entity’s standalone figures. Additionally, the company granted 1,07,700 Employee Stock Options on May 15, 2026, under the ESOP 2025 Scheme, with associated expenses recognized in the current quarter. The implementation of the New Labour Codes effective November 21, 2025, did not materially impact the financial results, as employee benefit structures were already aligned with the new framework.